Exelixis, Inc. (EX9.F)

20,00 -0,44 (-2,15 %) À la clôture : 04:20PM CEST

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000
https://www.exelixis.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 310

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Stelios Papadopoulos Ph.D.	Co-Founder & Chair of the Board	109,63k	S.O.	1948
Dr. Michael M. Morrissey Ph.D.	CEO, President & Director	2,01M	3,51M	1961
Mr. Christopher J. Senner	Executive VP & CFO	981,58k	651,32k	1968
Dr. Dana T. Aftab Ph.D.	Executive VP of Discovery and Translational Research & Chief Scientific Officer	818,68k	211,11k	1964
Mr. Jeffrey J. Hessekiel J.D.	Executive VP, General Counsel & Secretary	865,09k	382,45k	1969
Dr. Amy C. Peterson M.D.	Executive VP, Product Development & Medical Affairs and Chief Medical Officer	527,39k	S.O.	1967
Ms. Susan T. Hubbard	Executive Vice President of Public Affairs & Investor Relations	S.O.	S.O.	S.O.
Ms. Laura Dillard	Executive Vice President of Human Resources	S.O.	S.O.	S.O.
Dr. Peter Lamb Ph.D.	Executive VP of Scientific Strategy	843,18k	9,94M	1961
Dr. Anne Champsaur M.D.	Senior Vice President of Drug Safety	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Exelixis, Inc. en date du 1 mai 2024 est 3. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 4; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.